Form 4: Trevi Therapeutics Director Anne Vanlent Granted 45,000 Stock Options

Trevi Therapeutics, Inc. Director Anne Vanlent was granted 45,000 nonstatutory stock options with an exercise price of $6.25, vesting over the next year.

Summary

• Director Anne Vanlent of Trevi Therapeutics, Inc. (TRVI) was granted 45,000 nonstatutory stock options on June 11, 2025.
• The options have an exercise price of $6.25 per share.
• The options were granted at a price of $0.00, meaning the option itself was free, but the underlying shares must be purchased at the exercise price.
• These options are scheduled to fully vest on the earlier of June 11, 2026 (the first anniversary of the grant date) or the date of the next annual meeting of stockholders, contingent on Ms. Vanlent's continued service as a director, employee, or consultant.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Ms. Vanlent beneficially owns 45,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive signal of alignment between management/board and shareholder interests, as the options' value is tied to future stock price appreciation. It's a routine compensation event, so the positive impact is moderate rather than significant.

Positives

• The grant of stock options to a director aligns the director's interests with those of shareholders, as the options gain value if the stock price increases above the exercise price.
• The long expiration date (June 10, 2035) provides a significant window for the options to become in-the-money.

Risks

• The value of the granted options is contingent on the future performance of Trevi Therapeutics' stock price; if the stock price does not exceed the $6.25 exercise price, the options may expire worthless.
• The vesting of the options is subject to the recipient's continued service, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The granted stock options are scheduled to fully vest on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders, subject to the director's continued service. The options have a long-term expiration date of June 10, 2035, indicating a long-term incentive.

Industry Context

This filing is a routine disclosure of equity compensation for a director in the biotechnology/pharmaceutical industry. Granting stock options is a common practice to incentivize and retain key personnel, aligning their interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice across publicly traded companies, including those in the biotechnology and pharmaceutical sectors, as a form of non-cash compensation.
• The exercise price of $6.25 is the market price at the time of grant, which is typical for nonstatutory stock options to ensure alignment with future stock performance.
• The vesting schedule, tied to continued service and an annual meeting or one-year anniversary, is a common structure designed to retain directors and incentivize long-term commitment.
• The 10-year expiration period (until June 10, 2035) is also a common duration for employee and director stock options, providing ample time for the company's value to appreciate.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholders, as the options gain value only if the stock price increases, potentially incentivizing decisions that enhance shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Management/Board: Reinforces the compensation structure for directors, potentially aiding in retention and motivation.

Next Steps

• The granted options will vest on the earlier of June 11, 2026, or the date of Trevi Therapeutics' next annual meeting of stockholders, subject to continued service.
• Anne Vanlent may choose to exercise these options at any point after vesting and before the expiration date of June 10, 2035, assuming the stock price is above the exercise price of $6.25.

Key Dates

Keywords

Trevi Therapeutics, TRVI, SEC Form 4, Stock Option Grant, Director Compensation, Insider Ownership, Equity Compensation, Anne Vanlent